1. Market Research
  2. > Aradigm Corporation – Product Pipeline Review – 2013

Aradigm Corporation – Product Pipeline Review – 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 21 pages

Aradigm Corporation – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Aradigm Corporation - Product Pipeline Review - 2013” provides data on the Aradigm Corporation’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Aradigm Corporation’s corporate website, SEC filings, investor presentations and featured press releases, both from Aradigm Corporation and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Aradigm Corporation - Brief Aradigm Corporation overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Aradigm Corporation human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Aradigm Corporation with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Aradigm Corporation’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Aradigm Corporation’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Aradigm Corporation in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Aradigm Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Aradigm Corporation.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Aradigm Corporation and identify potential opportunities in those areas.

Table Of Contents

Aradigm Corporation - Product Pipeline Review - 2013
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Aradigm Corporation Snapshot 4
Aradigm Corporation Overview 4
Key Information 4
Key Facts 4
Aradigm Corporation - Research and Development Overview 5
Key Therapeutic Areas 5
Aradigm Corporation - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Aradigm Corporation - Pipeline Products Glance 9
Aradigm Corporation Clinical Stage Pipeline Products 9
Phase I Products/Combination Treatment Modalities 9
Aradigm Corporation - Early Stage Pipeline Products 10
Pre-Clinical Products/Combination Treatment Modalities 10
Aradigm Corporation - Drug Profiles 11
ARD-1600 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
ciprofloxacin Liposomal 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
Aradigm Corporation - Pipeline Products by Route of Administration 13
Aradigm Corporation - Pipeline Products By Mechanism of Action 14
Aradigm Corporation - Dormant Projects 15
Aradigm Corporation - Discontinued Pipeline Products 16
Aradigm Corporation - Company Statement 17
Aradigm Corporation - Locations And Subsidiaries 19
Head Office 19
Appendix 20
Methodology 20
Coverage 20
Secondary Research 20
Primary Research 20
Expert Panel Validation 20
Contact Us 21
Disclaimer 21

List of Tables

Aradigm Corporation, Key Information 4
Aradigm Corporation, Key Facts 4
Aradigm Corporation - Pipeline by Indication, 2013 6
Aradigm Corporation - Pipeline by Stage of Development, 2013 7
Aradigm Corporation - Monotherapy Products in Pipeline, 2013 8
Aradigm Corporation - Phase I, 2013 9
Aradigm Corporation - Pre-Clinical, 2013 10
Aradigm Corporation - Pipeline By Route of Administration, 2013 13
Aradigm Corporation - Pipeline Products By Mechanism of Action, 2013 14
Aradigm Corporation - Dormant Developmental Projects,2013 15
Aradigm Corporation - Discontinued Pipeline Products, 2013 16

List of Figures

Aradigm Corporation - Pipeline by Indication, 2013 6
Aradigm Corporation - Pipeline by Stage of Development, 2013 7
Aradigm Corporation - Monotherapy Products in Pipeline, 2013 8
Aradigm Corporation - Pipeline Products By Mechanism of Action, 2013 14

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.